Showing results (121-130 of 171) with videos related to

Sort By:
Pageof 18
International Journal of Cancer|January 25, 2018
EML4-ALK fusion variant V3 is a high-risk feature conferring accelerated metastatic spread, early treatment failure and worse overall survival in ALK+ non-small cell lung cancerPetros Christopoulos, Volker Endris, Farastuk Bozorgmehr, et al.
Cancers|January 24, 2019
Detection of TP53 Mutations in Tissue or Liquid Rebiopsies at Progression Identifies ALK+ Lung Cancer Patients with Poor SurvivalPetros Christopoulos, Steffen Dietz, Martina Kirchner, et al.
Clinical Lung Cancer|April 29, 2026
A Retrospective, Multicenter Analysis Within the National Network Genomic Medicine Lung Cancer in Germany to Detect RET Fusions as a Possible Mechanism of Resistance in Patients With EGFR MutationsCornelia Kropf-Sanchen, Nikolaj Frost, Jonas Kuon, et al.
BMJ Open|March 27, 2025
NeoTRACK trial: Neoadjuvant TiRagolumab, Atezolizumab and Chemotherapy - dissection of IO- efficacy in NSCLC by longitudinal tracKing - protocol of a non-randomised, open-label, single-arm, phase II studyRomina M Roesch, Johannes Schnorbach, Laura V Klotz, et al.
International Journal of Molecular Sciences|July 27, 2022
Specific Targeting of Antiapoptotic Bcl-2 Proteins as a Radiosensitizing Approach in Solid TumorsBenjamin Sobol, Osama Azzam Nieto, Emily Lara Eberlein, et al.
British Journal of Cancer|May 19, 2026
Differential effects of prior versus concomitant Steroid and Antibiotic Treatment on Immunotherapy Efficacy - A Pooled Analysis of the RAMONA, INTEGA, OPTIM, ELDORANDO, FORCE, TITAN-RCC and TITAN-TCC Trials of the German AIO Study GroupIsabella C Wiest, Lena Dreikhausen, Ralph Keller, et al.
Cancer Cell|January 5, 2024
Interferon-stimulated neutrophils as a predictor of immunotherapy responseMadeleine Benguigui, Tim J Cooper, Prajakta Kalkar, et al.
Clinical Lung Cancer|June 29, 2026
Outcomes of Platinum Plus Pemetrexed and Treatment Patterns Following First-Line Nivolumab and Ipilimumab in Pleural Mesothelioma: Real-World Results From the German MesoNet StudyRajiv Shah, Eva L Buchmeier, Hans-Georg Kopp, et al.
Ebiomedicine|November 8, 2020
Longitudinal therapy monitoring of ALK-positive lung cancer by combined copy number and targeted mutation profiling of cell-free DNASteffen Dietz, Petros Christopoulos, Zhao Yuan, et al.
International Journal of Cancer|April 20, 2026
Neoadjuvant Atezolizumab and Chemotherapy for Non-Squamous Non-Small Cell Lung Cancer: Efficacy and Safety Results of an Open-Label, Single-Arm, Phase II TrialBenedikt Niedermaier, Tilmann Bochtler, Florian Eichhorn, et al.
Pageof 18